What Is R&D?
Research and development covers the work companies do to create what they will sell tomorrow: laboratory research, drug discovery and clinical trials, engineering of new products, and development of new software and technology platforms. On the income statement it appears as its own operating expense line below gross profit, alongside selling, general and administrative costs.
R&D intensity varies enormously by industry. Large pharmaceutical companies routinely spend 15% to 25% of revenue on R&D, and major technology platforms spend at similar levels in absolute terms, with several exceeding $30 billion annually. At the other extreme, retailers and utilities may report essentially none. That variation makes R&D as a percentage of revenue a standard benchmarking metric within sectors.
How Accounting Rules Treat It
US GAAP, under ASC 730, requires companies to expense research and development costs as incurred, on the theory that future benefits are too uncertain to justify an asset. The main exceptions involve software: development costs for software to be sold can be capitalized after technological feasibility is established, and internal-use software development is capitalized during the application development stage. In practice many software companies capitalize little because feasibility arrives close to release.
IFRS takes a different view. IAS 38 still expenses pure research, but requires capitalizing development costs once a project demonstrates technical feasibility and probable future economic benefit, among other criteria. As a result, an IFRS-reporting automaker or software firm can show higher near-term profits and a development asset on its balance sheet, a gap analysts must adjust for in cross-border comparisons. R&D acquired in an acquisition is also capitalized as in-process R&D under purchase accounting.
Why It Matters to Investors and Analysts
Because R&D is expensed immediately while its payoff arrives years later, GAAP earnings systematically understate the economics of research-heavy businesses. A pharma company plowing 20% of revenue into its pipeline looks less profitable today than a peer harvesting old products, even if it is creating far more value. Some analysts respond by capitalizing R&D themselves, rebuilding earnings and invested capital as if research spending were amortized over five to ten years, which meaningfully changes metrics like return on invested capital.
R&D also features in earnings-quality and valuation debates. Cutting research is one of the fastest ways to hit a quarterly earnings target at the expense of the future, so a declining R&D-to-revenue ratio at a growth company warrants questions. In M&A and equity research, pipeline value at biotech and pharma names is often modeled separately from the base business precisely because the expensed R&D creating it never shows up as an asset.
